New Drugs FDA Approves Bydureon (exenatide extended-release) for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control 8 years ago
Pharma Industry News Jim Miller Presents Contract Services Keynote at CPhI North America 2018 8 years ago